tiprankstipranks
Japan Medical Dynamic Marketing, Inc. (JP:7600)
:7600
Japanese Market
Want to see JP:7600 full AI Analyst Report?

Japan Medical Dynamic Marketing, Inc. (7600) AI Stock Analysis

0 Followers

Top Page

JP:7600

Japan Medical Dynamic Marketing, Inc.

(7600)

Select Model
Select Model
Select Model
Neutral 56 (OpenAI - 5.2)
Rating:56Neutral
Price Target:
¥833.00
▲(71.05% Upside)
Action:Reiterated
Date:05/23/26
The score is held back primarily by weakening financial performance—especially the sharp deterioration in cash generation and compressed margins—despite a still-manageable balance sheet. Technicals are a clear positive with strong upward price momentum, but valuation remains a concern due to the high P/E relative to the current fundamental backdrop.
Positive Factors
Balance sheet health
A large equity base and only moderate leverage provide a durable financial buffer. Growing assets and equity increase flexibility for investment or refinancing, lowering insolvency risk and supporting strategic choices over the next 2–6 months even if operating results remain uneven.
Negative Factors
Severe cash-flow deterioration
Sharp negative free cash flow and operating cash flow roughly 0.03x of net income indicate earnings are not translating into liquidity. This undermines capacity to fund capex, working capital, dividends, or debt service without drawing on reserves or raising capital, a material medium-term risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet health
A large equity base and only moderate leverage provide a durable financial buffer. Growing assets and equity increase flexibility for investment or refinancing, lowering insolvency risk and supporting strategic choices over the next 2–6 months even if operating results remain uneven.
Read all positive factors

Japan Medical Dynamic Marketing, Inc. (7600) vs. iShares MSCI Japan ETF (EWJ)

Japan Medical Dynamic Marketing, Inc. Business Overview & Revenue Model

Company Description
Japan Medical Dynamic Marketing, Inc. (JMDM) engages in the development, production, importation, and distribution of medical instruments throughout Japan and the United States. Its product portfolio features a variety of trauma devices, including...
How the Company Makes Money
null...

Japan Medical Dynamic Marketing, Inc. Financial Statement Overview

Summary
Fundamentals have deteriorated: revenue turned negative in 2026 (-4.26% YoY) and profitability compressed sharply (net margin ~1.1%, operating margin ~2.4%). The balance sheet is still reasonably leveraged (debt/equity ~0.23), but cash flow is the key weakness—operating cash flow dropped and free cash flow is deeply negative in 2026 (-1.75bn), indicating stressed financial quality despite a return to profitability after 2025.
Income Statement
52
Neutral
Balance Sheet
63
Positive
Cash Flow
34
Negative
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue24.98B23.92B25.11B23.18B21.31B19.19B
Gross Profit14.46B12.74B15.65B14.76B13.99B12.99B
EBITDA1.03B2.19B1.40B3.27B3.35B4.21B
Net Income-669.47M263.14M-461.80M1.27B1.42B2.14B
Balance Sheet
Total Assets32.22B35.68B33.83B31.49B29.43B27.34B
Cash, Cash Equivalents and Short-Term Investments2.35B3.11B3.18B2.32B2.80B2.59B
Total Debt4.31B5.87B3.29B1.49B1.87B1.85B
Total Liabilities8.25B10.25B9.09B5.88B6.14B5.85B
Stockholders Equity23.96B25.40B24.68B25.51B23.16B21.39B
Cash Flow
Free Cash Flow0.00-1.75B-504.10M302.45M870.67M1.53B
Operating Cash Flow0.00205.55M1.05B2.10B2.19B3.11B
Investing Cash Flow0.00-2.00B-1.67B-1.80B-1.48B-1.75B
Financing Cash Flow0.001.65B1.49B-840.71M-514.78M-1.29B

Japan Medical Dynamic Marketing, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price487.00
Price Trends
50DMA
641.08
Positive
100DMA
585.63
Positive
200DMA
536.62
Positive
Market Momentum
MACD
47.26
Positive
RSI
63.00
Neutral
STOCH
41.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7600, the sentiment is Positive. The current price of 487 is below the 20-day moving average (MA) of 784.85, below the 50-day MA of 641.08, and below the 200-day MA of 536.62, indicating a bullish trend. The MACD of 47.26 indicates Positive momentum. The RSI at 63.00 is Neutral, neither overbought nor oversold. The STOCH value of 41.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7600.

Japan Medical Dynamic Marketing, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
¥17.12B12.893.02%13.43%7.06%
61
Neutral
¥225.54B15.111.92%4.29%3.92%
56
Neutral
¥21.09B80.123.12%-4.77%
56
Neutral
¥89.01B23.542.31%3.35%74.40%
53
Neutral
¥57.01B372.68-0.46%-12.27%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
¥135.60B274.832.42%3.73%0.78%-95.37%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7600
Japan Medical Dynamic Marketing, Inc.
801.00
264.24
49.23%
JP:7779
CYBERDYNE
270.00
95.00
54.29%
JP:6523
PHC Holdings Corp.
1,070.00
201.23
23.16%
JP:4549
Eiken Chemical Co., Ltd.
2,700.00
546.29
25.36%
JP:6678
Techno Medica Co., Ltd.
2,009.00
201.81
11.17%
JP:6849
Nihon Kohden Corporation
1,351.00
-313.48
-18.83%

Japan Medical Dynamic Marketing, Inc. Corporate Events

Japan Medical Dynamic Marketing Denies Report of Launching Take-Private Bid
May 13, 2026
Japan Medical Dynamic Marketing, Inc. has refuted a recent paid English-language media report claiming the company has launched a bidding process to go private, stating that the information did not originate from the company. Management acknowledg...
Japan Medical Dynamic Marketing Sets Out FY2026 Results and RT500 Long-Term Plan
May 12, 2026
Japan Medical Dynamic Marketing has released materials for its financial results briefing for the fiscal year ended March 2026, detailing consolidated net sales, income statements, and sales breakdowns by major product categories and regions, incl...
Japan Medical Dynamic Marketing Swings to Profit but Warns of Sharper Earnings Decline Ahead
May 8, 2026
Japan Medical Dynamic Marketing reported a 4.8% decline in net sales to ¥23.9 billion for the year ended March 31, 2026, with operating profit dropping 63.1% to ¥574 million and ordinary profit down 64.1%, though it swung to a profit att...
Japan Medical Dynamic Marketing Misses Forecasts but Holds Dividend as Deferred Tax Write-Down Weighs on Profit
May 8, 2026
Japan Medical Dynamic Marketing reported that its full-year results for the fiscal year ended March 31, 2026 fell short of its earlier forecasts, with net sales and operating profit declining due to fewer surgical cases in Japan following adverse ...
Japan Medical Dynamic Marketing Reshapes Auditor Lineup to Bolster Governance
Mar 27, 2026
Japan Medical Dynamic Marketing, Inc. announced a change in its audit structure following the resignation of full-time auditor Katsuhiko Seshita, effective March 31, 2026, due to personal reasons. As of April 1, 2026, Yoshiaki Jitto will become a ...
Japan Medical Dynamic Marketing Overhauls Governance and Executive Lineup
Mar 27, 2026
Japan Medical Dynamic Marketing, Inc. will shift its governance structure from a company with a Board of Company Auditors to a company with an Audit and Supervisory Committee, pending shareholder approval at its June 19, 2026 annual meeting. The b...
Japan Medical Dynamic Marketing Plans Governance Shift and Electronic Disclosure Move
Mar 27, 2026
Japan Medical Dynamic Marketing will ask shareholders at its June 19, 2026 annual meeting to approve a shift from a traditional company auditor structure to a Company with an Audit and Supervisory Committee and to move its public notices to an ele...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 23, 2026